search
Back to results

Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer

Primary Purpose

Infertility

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Granulocyte Colony Stimulating Factor
Platelet Rich Plasma Arm
Saline
Sponsored by
Wael Elbanna Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring GCSF, PRP, Pregnancy

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • All women aged 20-40 years
  • non-smoker
  • BMI < 30
  • Normal endometrial cavity confirmed by hysteroscopy
  • Visiting the center for IVF by frozen embryo transfer during the period of the study

Exclusion Criteria:

  • History of anti-phospholipid syndrome confirmed by serological tests.
  • History of any hematological and immunological disorders
  • History of chromosomal or genetic abnormalities in the patient or in the family
  • Any uterine abnormalities (congenital or acquired)
  • Previous uterine surgeries except caesarean section
  • Hypersensitivity to G-CSF
  • Uncontrolled systemic disease

Sites / Locations

  • Hayat center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Granulocyte Colony Stimulating Factor Arm

Platelet Rich Plasma Arm

Saline

Arm Description

Women in this group will receive G-CSF with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.

Women in this group will receive PRP with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.

Women in this group will receive saline with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.

Outcomes

Primary Outcome Measures

The clinical pregnancy rate
The clinical pregnancy rate

Secondary Outcome Measures

Chemical pregnancy rate
Chemical pregnancy rate
endometrial thickness
endometrial thickness in all groups (histopathology & TVUS)
Implantation rate
Implantation rate
Miscarriage rate
Miscarriage rate
Live-birth rate
Live-birth rate

Full Information

First Posted
May 8, 2019
Last Updated
October 12, 2023
Sponsor
Wael Elbanna Clinic
Collaborators
National Research Centre, Egypt
search

1. Study Identification

Unique Protocol Identification Number
NCT03945812
Brief Title
Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer
Official Title
The Impact of Using Granulocyte Colony Stimulating Factor (G-CSF) Versus Platelet Rich Plasma (PRP) on the Outcomes of Frozen Embryo Transfer; Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
April 15, 2021 (Actual)
Study Completion Date
March 8, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wael Elbanna Clinic
Collaborators
National Research Centre, Egypt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The rationale behind this current study is to assess the impact of using PRP versus GCSF on the outcomes of frozen embryo transfer in term of clinical pregnancy rates.
Detailed Description
INTRODUCTION AND STUDY RATIONALE Despite the advancements in the treatment of infertility, repeated failure of implantation continues as a challenging difficulty. Embryo implantation is affected by many factors. Many efforts were made to improve the implantation rate by different methods blastocyst transfer, assisted hatching, preimplantation genetic screening, hysteroscopy, removal of hydrosalpinges and endometrial scratch. Furthermore, infertility specialists suggested some empirical methods like the infusion in the uterine cavity of platelet-rich plasma (PRP) in patients with thin endometrium which has been shown to be effective in improving the pregnancy rate. Another factor is granulocyte colony stimulating factor (G-CSF) which has receptors in endometrial cells and may have a role in implantation. The use of G-CSF in assisted reproductive technology (ART) has been tried by many research studies either via intrauterine or systemic administration. There is only one study compared the impact of PRP and GCSF administration on the pregnancy rate and on the endometrial thickness with a small sample size. The rationale behind this current study is to assess the impact of using PRP versus GCSF on the outcomes of frozen embryo transfer in term of clinical pregnancy rates. STUDY OBJECTIVES Primary: The primary objective of the study is to compare the clinical pregnancy rate determined by presence of fetal heart beat in transvaginal ultrasound after embryo transfer in all groups. Secondary: To compare the following in the three study arms: Chemical pregnancy determined by positive serum β-HCG, 2 weeks after embryo transfer. Clinical pregnancy rate adjusted by the endometrial thickness (thin versus normal) in all groups. Clinical pregnancy rate adjusted by PGS in all groups The midluteal endometrial thickness in all groups (histopathology & TVUS). The number of women who had thin endometrium and reaches endometrial thickness ≥ 7 mm after using G-CSF or PRP. Implantation rate Miscarriage rate Live-birth rate

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
GCSF, PRP, Pregnancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
390 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Granulocyte Colony Stimulating Factor Arm
Arm Type
Active Comparator
Arm Description
Women in this group will receive G-CSF with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.
Arm Title
Platelet Rich Plasma Arm
Arm Type
Active Comparator
Arm Description
Women in this group will receive PRP with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
Women in this group will receive saline with conventional hormonal therapy: Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed.
Intervention Type
Drug
Intervention Name(s)
Granulocyte Colony Stimulating Factor
Other Intervention Name(s)
Filgrastim
Intervention Description
Filgrastim, Amgen, California, USA 300 mg/1.0 mL
Intervention Type
Other
Intervention Name(s)
Platelet Rich Plasma Arm
Intervention Description
Platelet Rich Plasma Arm
Intervention Type
Other
Intervention Name(s)
Saline
Other Intervention Name(s)
Saline 9%
Intervention Description
Saline 9%
Primary Outcome Measure Information:
Title
The clinical pregnancy rate
Description
The clinical pregnancy rate
Time Frame
Up to 2 weeks
Secondary Outcome Measure Information:
Title
Chemical pregnancy rate
Description
Chemical pregnancy rate
Time Frame
Up to 2 weeks
Title
endometrial thickness
Description
endometrial thickness in all groups (histopathology & TVUS)
Time Frame
Up to 2 weeks
Title
Implantation rate
Description
Implantation rate
Time Frame
Up to 2 weeks
Title
Miscarriage rate
Description
Miscarriage rate
Time Frame
With second trimester
Title
Live-birth rate
Description
Live-birth rate
Time Frame
1 year

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All women aged 20-40 years non-smoker BMI < 30 Normal endometrial cavity confirmed by hysteroscopy Visiting the center for IVF by frozen embryo transfer during the period of the study Exclusion Criteria: History of anti-phospholipid syndrome confirmed by serological tests. History of any hematological and immunological disorders History of chromosomal or genetic abnormalities in the patient or in the family Any uterine abnormalities (congenital or acquired) Previous uterine surgeries except caesarean section Hypersensitivity to G-CSF Uncontrolled systemic disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wael SS Elbanna, Consultant
Organizational Affiliation
Wael Elbanna Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hayat center
City
Maadi
State/Province
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30859080
Citation
Mehrafza M, Kabodmehri R, Nikpouri Z, Pourseify G, Raoufi A, Eftekhari A, Samadnia S, Hosseini A. Comparing the Impact of Autologous Platelet-rich Plasma and Granulocyte Colony Stimulating Factor on Pregnancy Outcome in Patients with Repeated Implantation Failure. J Reprod Infertil. 2019 Jan-Mar;20(1):35-41.
Results Reference
background
PubMed Identifier
24269084
Citation
Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong K, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014 Jan;28(1):14-38. doi: 10.1016/j.rbmo.2013.08.011. Epub 2013 Sep 14.
Results Reference
background
PubMed Identifier
17674185
Citation
Rinehart J. Recurrent implantation failure: definition. J Assist Reprod Genet. 2007 Jul;24(7):284-7. doi: 10.1007/s10815-007-9147-4. Epub 2007 Aug 3.
Results Reference
background
PubMed Identifier
25785127
Citation
Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med. 2015 Jan 15;8(1):1286-90. eCollection 2015.
Results Reference
background

Learn more about this trial

Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer

We'll reach out to this number within 24 hrs